Donate Toggle Menu

Pronunciation: “yur-voy” (“ip-ee-LEE-mu-mab”)

Disclaimer: This patient information sheet summarizes the information as prescribed for treatment of advanced kidney cancer and is not meant to substitute for medical advice. If you would like more information, talk with your healthcare team. Every patient is different, and only you and your doctor can decide the best treatment plan for you. Please see our guide on talking to your doctor about treatments for kidney cancer.

Bristol-Myers Squibb (BMS)   

Patient Assistance Program
BMS Access Support

What type of drug is it?:  Immunotherapy.

How is it prescribed?: Yervoy is approved to be used in combination with nivolumab (Opdivo), and this combination is often referred to as Ipi/Nivo for short.

How is it administered?: This medication is given intravenously, also referred to an IV (meaning directly into a vein).

How often do I take it?: The ipilimumab/nivolumab (Ipi/Nivo) combination is given once every 3 weeks for a total of 4 doses.  Further infusions of nivolumab are continued every 2-4 weeks after these initial 4 combination doses.

If you miss a dose, please call your healthcare provider for guidance on how to proceed.

Storage: This will be handled by the infusion clinic.

Restrictions: None. Please see our guide on what to ask and tell your doctor before starting any medication.

Side Effects:   There can be a range of side effects for any medication. Letting your doctor know about these side effects does not mean you have to stop treatment – but may mean that your treatment needs to be adjusted. Therefore, it is important to let your doctor know if you are experiencing side effects so they can manage your medications appropriately. Please see our educational sheet on side effects for more information on what to watch out for and how to talk with your doctor should you experience any of them.   

Revised May 2022
Adapted from the package insert. Bristol-Myers Squibb, May 2022